Can-Fite BioPharma’s Promising Phase 3 Trial for Liver Cancer Treatment

Can-Fite BioPharma Ltd ((CANF)) announced an update on their ongoing clinical study.

Can-Fite BioPharma Ltd is conducting a significant Phase 3 clinical trial titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis. The study aims to assess the efficacy and safety of Namodenoson in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 cirrhosis, whose disease has progressed on at least one prior therapy.

The intervention being tested is Namodenoson, an adenosine A3 receptor agonist, administered orally at 25 mg twice daily. The purpose is to evaluate its potential in treating advanced HCC compared to a placebo.

This interventional study follows a randomized, parallel assignment model with quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded. The primary goal is treatment-focused, aiming to provide a new therapeutic option for this patient population.

The study began on December 21, 2021, and is currently recruiting participants. The last update was submitted on April 28, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s development and potential market entry.

The successful outcome of this study could positively impact Can-Fite BioPharma’s stock performance by enhancing investor confidence and potentially increasing the company’s market share in the oncology sector. It also positions Can-Fite as a competitive player in the treatment of liver cancer, an area with significant unmet medical needs.

The study is ongoing, with further details available on the ClinicalTrials portal.